GVHD is Maintained by Tissue-Resident TCF-1+ T Cells

Article

Alex Kradhim reviews how graft-versus-host disease can be maintained by tissue resident TCF-1+ T cells.

Researchers from the University of Pittsburgh have recently published an article demonstrating that progenitor-like T cells locally maintain graft-versus-host disease (GVHD) in affected tissues, independent of blood-derived T cells, in a mouse model. This is believed to be due primarily to tissue resident TCF-1+ T cells, which are preferentially engrafted, expanded, and differentiated into effectors on adoptive transfer. These findings, published in the journal Immunity, help improve our overall understanding of GVHD maintenance and progression and potentially allow for more targeted GVHD therapies.

The mechanism by which the alloreactive T cell response is initiated and maintained in GVHD is currently not well known. There are two main hypotheses for GVHD maintenance: that T cells are continually activated in secondary lymphoid tissues (SLTs) and recruited to tissues, and that T cells are maintained within tissues through inputs from blood-derived T cells. Since neither model can explain how GVHD is maintained despite T cell exhaustion, the authors performed detailed T cell clone analysis and parabiosis to answer this question.

To delineate this mechanism, the authors used T cell receptor (TCR) transgenic GVHD models and found that there was a gradual switch from early distribution of clones to tissues to a locally maintained GVHD response. Mathematical modelling of clonal frequencies suggested that clonal compositions in SLT and target tissues did not become more related, and that new T cells in a given tissue must be locally derived. These findings suggested that GVHD is maintained in target tissues by a subset of progenitor-like cells. The results from parabiosis experiments, which tracked miHA-reactive CD4+ and CD8+ T cells to determine the source of T cells, further demonstrated a local GVHD maintenance. Lastly, single cell RNA-seq (scRNA-seq) experiments identified a cluster of Tcf7 (TCF-1) expressing T cells which maintain effector cells in GVHD affected tissues. Taken together, these findings demonstrate that progenitor-like T cells maintain GVHD locally.

Reference

Sacirbegovic F, Günther M, Greco A, et al. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023;56(2):369-385.e6. doi.org/10.1016/j.immuni.2023.01.00

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content